<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824070</url>
  </required_header>
  <id_info>
    <org_study_id>575</org_study_id>
    <nct_id>NCT00824070</nct_id>
  </id_info>
  <brief_title>Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects</brief_title>
  <official_title>An Open-Label, Randomized Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects After a Single Topical Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the concentration of besifloxacin, moxifloxacin, or
      gatifloxacin in aqueous humor samples collected following topical instillation of the
      associated formulation in subjects undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Aqueous Humor Drug Concentration.</measure>
    <time_frame>Visit 2, 1-14 days following screening visit</time_frame>
    <description>An aqueous humor specimen was collected from the study eye for determination of drug concentration 60 min after study drug instillation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Cataract Extraction</condition>
  <arm_group>
    <arm_group_label>Besifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Besifloxacin ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vigamox (moxifloxacin ophthalmic solution, 0.5%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gatifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zymar (gatifloxacin ophthalmic solution, 0.3%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifloxacin hydrochloride</intervention_name>
    <description>Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.</description>
    <arm_group_label>Besifloxacin</arm_group_label>
    <other_name>Besivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin hydrochloride</intervention_name>
    <description>Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Vigamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gatifloxacin</intervention_name>
    <description>Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.</description>
    <arm_group_label>Gatifloxacin</arm_group_label>
    <other_name>Zymar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are a candidate for a routine, uncomplicated, primary cataract
             extraction.

          -  Subjects who, in the Investigator's opinion, have potential for postoperative best
             corrected Snellen visual acuity of at least 20/200 in the study eye.

        Exclusion Criteria:

          -  Subjects who have a known sensitivity, contraindication, or allergy to the study
             medication(s) or their components.

          -  Subjects who had any corneal refractive surgery in the study eye.

          -  Subjects who have a history or presence of chronic generalized systemic disease that
             the Investigator feels might increase the risk to the subject or confound the result
             of the study.

          -  Subjects who had ocular surgery in the study eye, including laser procedures, within
             the past 6 months.

          -  Subjects who have taken any topical ocular medication in the study eye, other than
             those required by the protocol and permitted for surgery, during the 24 hours prior to
             the study medication being instilled.

          -  Subjects who use any antibiotics (e.g., systemic or topical) within the 7 days prior
             to the surgery date.

          -  Subjects who are monocular.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Donnefeld</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Long Island</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Rockville Center</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>September 30, 2010</results_first_submitted>
  <results_first_submitted_qc>September 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2010</results_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Gatifloxacin</mesh_term>
    <mesh_term>7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted a 6 sites in the US. This was a single dose study with first patient enrollment on 2/2/2009 and last patient visit was 7/9/2009.</recruitment_details>
      <pre_assignment_details>105 subjects were screened at Visit 1 and qualified subjects returned on the day of surgery (Visit 2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Besifloxacin</title>
          <description>Besifloxacin ophthalmic suspension</description>
        </group>
        <group group_id="P2">
          <title>Moxifloxacin</title>
          <description>Vigamox (moxifloxacin ophthalmic solution, 0.5%)</description>
        </group>
        <group group_id="P3">
          <title>Gatifloxacin</title>
          <description>Zymar (gatifloxacin ophthalmic solution, 0.3%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Besifloxacin</title>
          <description>Besifloxacin ophthalmic suspension</description>
        </group>
        <group group_id="B2">
          <title>Moxifloxacin</title>
          <description>Vigamox (moxifloxacin ophthalmic solution, 0.5%)</description>
        </group>
        <group group_id="B3">
          <title>Gatifloxacin</title>
          <description>Zymar (gatifloxacin ophthalmic solution, 0.3%)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="8.1"/>
                    <measurement group_id="B2" value="4" spread="9.9"/>
                    <measurement group_id="B3" value="5" spread="9.6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Aqueous Humor Drug Concentration.</title>
        <description>An aqueous humor specimen was collected from the study eye for determination of drug concentration 60 min after study drug instillation.</description>
        <time_frame>Visit 2, 1-14 days following screening visit</time_frame>
        <population>Statistical Analysis of AH Drug Concentration. Modified intent to treat population (mITT). Subjects with non-missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Besifloxacin</title>
            <description>Besifloxacin ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin</title>
            <description>Vigamox (moxifloxacin ophthalmic solution, 0.5%)</description>
          </group>
          <group group_id="O3">
            <title>Gatifloxacin</title>
            <description>Zymar (gatifloxacin ophthalmic solution, 0.3%)</description>
          </group>
        </group_list>
        <measure>
          <title>The Aqueous Humor Drug Concentration.</title>
          <description>An aqueous humor specimen was collected from the study eye for determination of drug concentration 60 min after study drug instillation.</description>
          <population>Statistical Analysis of AH Drug Concentration. Modified intent to treat population (mITT). Subjects with non-missing data.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1349" spread="0.5820"/>
                    <measurement group_id="O2" value="0.6681" spread="0.4980"/>
                    <measurement group_id="O3" value="0.1251" spread="0.07624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Single ocular administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Besifloxacin</title>
          <description>Besifloxacin ophthalmic suspension</description>
        </group>
        <group group_id="E2">
          <title>Moxifloxacin</title>
          <description>Vigamox (moxifloxacin ophthalmic solution, 0.5%)</description>
        </group>
        <group group_id="E3">
          <title>Gatifloxacin</title>
          <description>Zymar (gatifloxacin ophthalmic solution, 0.3%)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s)after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All drug concentrations were significantly below MIC90 values for relevant staphylococcal species.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tuyen Ong, MD</name_or_title>
      <organization>Bausch &amp; Lomb Inc</organization>
      <phone>(973) 360-6389</phone>
      <email>tuyen.ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

